
Feb 16 (Reuters) - Bristol-Myers Squibb Co BMY.N:
BRISTOL-MYERS SQUIBB CO - NEW FIVE-YEAR SOTYKTU (DEUCRAVACITINIB) DATA SHOW CONSISTENT SAFETY AND DURABLE RESPONSE RATES IN MODERATE-TO-SEVERE PLAQUE PSORIASIS
Source text: ID:nBw89WLb6a
Further company coverage: BMY.N